Abstract
In their longitudinal survey of more than 8,000 patients with episodic migraine and selected comorbidities, Drs. Lipton et al. reported the results of the CaMEO Study. The investigators used 3 unique mathematical models to estimate the effect of various comorbidities on the progression of episodic migraine to chronic migraine. All comorbidity classes independently contributed to disease progression, and the effect was cumulative—with more comorbidities conferring a greater risk than fewer comorbidities. Dr. Gupta expresses concerns regarding the usefulness of classifying migraine subtypes, as there is presently unclear biologic heterogeneity of various migraine phenotypes. In response, the authors emphasize the importance of distinguishing unique migraine syndromes, as they may signify distinct biomarkers of disease or demonstrate a differential responsiveness to certain therapeutics. The authors acknowledge that the results of this study are one of several steps, which may lead to the improved care of patients with migraine. In their longitudinal survey of more than 8,000 patients with episodic migraine and selected comorbidities, Drs. Lipton et al. reported the results of the CaMEO Study. The investigators used 3 unique mathematical models to estimate the effect of various comorbidities on the progression of episodic migraine to chronic migraine. All comorbidity classes independently contributed to disease progression, and the effect was cumulative—with more comorbidities conferring a greater risk than fewer comorbidities. Dr. Gupta expresses concerns regarding the usefulness of classifying migraine subtypes, as there is presently unclear biologic heterogeneity of various migraine phenotypes. In response, the authors emphasize the importance of distinguishing unique migraine syndromes, as they may signify distinct biomarkers of disease or demonstrate a differential responsiveness to certain therapeutics. The authors acknowledge that the results of this study are one of several steps, which may lead to the improved care of patients with migraine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.